1659-P: A Systematic Review of Trends in All-Cause Mortality among People with Diabetes

292-OR: Oral Semaglutide and Cardiovascular Outcomes by Baseline A1C and BMI in People with Type 2 Diabetes in the SOUL Trial

1397-P: Real-World Evidence on the Legacy Effect of Early vs. Late Glycaemic Reduction and All-Cause Mortality in Newly Diagnosed Type 2 Diabetes

85-LB: CGM Outcomes and Hypoglycemia Duration with Once-Weekly Insulin Icodec vs. Once-Daily Insulin Glargine U100 in Insulin-Naïve T2D—ONWARDS 1 Exploratory Analysis

1973-LB: Glucagon-Like Peptide 1 Receptor Agonist with Basal Insulin vs. Basal-Bolus Regimen on Glycemic Variability and Time-in-Range in Type 2 Diabetes Patients with Chronic Kidney Disease—A Randomised Controlled Trial

1220-P: Sotagliflozin Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA1c Level at 52 Weeks in Adults with T1D

1304-P: Trends in Use of Medications for Multifactorial Cardiovascular Risk Factor Intervention in Adults with Diabetes in Hong Kong, 2002–2019

331-OR: Modelling the Legacy Effect of Glycaemic Exposure on Long-Term Cardiovascular Disease in Newly Diagnosed Type 2 Diabetes

Trends in all-cause mortality among people with diagnosed diabetes in high-income settings: a multicountry analysis of aggregate data

388-P: Interrelationship between Hypoglycemia and CV and Mortality Outcomes in Type 2 Diabetes in the CARMELINA Trial

924-P: Predictors of Diabetes-Related Distress following Closed-Loop Initiation in Adults with Type 1 Diabetes in the UK—Insights from the Association of British Clinical Diabetologists

1867-LB: A Real-World Study Assessing the Efficacy and Safety of Switching from Basal–Bolus Insulin Therapy to Once-Daily iGlarLixi in People with Type 2 Diabetes—Soli De-escalation

934-P: Diabetes Technology across the Lifespan (Ages 2–89 Years)—Insights from the Technology Report on Surprising Usage Trends in Older Age Groups in Austria, Germany, and Switzerland

233-OR: Impact of Nocturnal Hypoglycemia on Daily Sleep Quality, Mood, and Alertness among Adults with Type 1 Diabetes: The Hypo-METRICS (Hypoglycaemia Measurement, Thresholds, and Impacts) Study

1924-LB: Clinical Performance of a Novel CGM System

Consistent Outcomes with Canagliflozin (CANA) in Patients with Type 2 Diabetes across Geographic Regions—Results from the CANagliflozin CardioVascular Assessment Study (CANVAS) Program